推官网,引流量

直推官网引流,大量子站导流 效果持久显著

批量建站,提收录

形成站群推广模式 让搜索引擎大量收录!

提权重,树权威

实现权重提升 树立行业权威

部署快,自主可控

免费下载

省成本,提效率

多分站齐推广,性价比高 批量数据分析,帮助及时调整优化

关于OD
关于OD
5月16日晚,昆山奥体中心,江苏足球超等联赛迎来精彩对决,苏州队镇守主场迎战连云
关于OD
188金宝博官网app下载 5月16日晚,苏超苏州主场迎战连云港,上海戏校校长、
关于OD
北京时刻5月20日凌晨1点,2026年谷歌I/O大会矜重演出,AI依旧是弥散的主
【【【序论:iQOO的数字系列旗舰,迎来了新成员】】】 无人不晓,在iQOO的旗
本翰墨数:1294,阅读时长简短2分钟 作家|第一财经何涛 封图|“耿同学讲故事
5月15日,英伟达CEO黄仁勋现身北京南锣饱读巷吃炸酱面,高清镜头捕捉到其指甲灰

OD资讯

ODZIXUN

OD资讯

查看更多
  • OD体育

    OD体育

  • 关于OD

    关于OD

  • OD资讯

    OD资讯

  • OD盘口

    OD盘口

OD盘口

  • OD盘口

OD体育(ODSports)官网入口

临床医学名词词典
首页 > 按专业查询名词 > 查询PubMed相关文献
名词信息
Pubmed相关的文献
familial mixed hypercholesterolemia 相关文献:
Inclisiran: First Approval.
Lamb YN.
Drugs. 2021 Feb;81(3):389-395. doi: 10.1007/s40265-021-01473-6.
PMID:33620677
Tafolecimab: First Approval.
Keam SJ.
Drugs. 2023 Nov;83(16):1545-1549. doi: 10.1007/s40265-023-01952-y.
PMID:37847461
Research advances in current drugs targeting hyperlipidemia (Review).
Zhao H, Wang Y, Li Y, Cheng R, Chen W.
Mol Med Rep. 2025 Oct;32(4):258. doi: 10.3892/mmr.2025.13623. Epub 2025 Jul 19.
PMID:40682836
Recaticimab: First Approval.
Lamb YN.
Drugs. 2025 Aug;85(8):1067-1072. doi: 10.1007/s40265-025-02199-5. Epub 2025 Jun 23.
PMID:40545518
Addressing the underdiagnosis of familial hypercholesterolemia: A mixed methods study exploring the knowledge and practice behaviors of cardiology healthcare providers.
Kalia I, Shope R, Reilly M, Schwartz L.
J Clin Transl Sci. 2023 Apr 5;7(1):e92. doi: 10.1017/cts.2023.519. eCollection 2023.
PMID:37125063
Familial combined hyperlipidaemia/polygenic mixed hyperlipidaemia.
Pedro-Botet J, Climent E, Gabarró N, Millán J.
Clin Investig Arterioscler. 2021 May;33 Suppl 2:43-49. doi: 10.1016/j.arteri.2020.12.013.
PMID:34006353
Rosuvastatin.
Carswell CI, Plosker GL, Jarvis B.
Drugs. 2002;62(14):2075-85; discussion 2086-7. doi: 10.2165/00003495-200262140-00008.
PMID:12269853
Ezetimibe.
Sizar O, Nassereddin A, Talati R.
2023 Aug 28. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
PMID:30422474
Reducing Premature Coronary Artery Disease in Malaysia by Early Identification of Familial Hypercholesterolemia Using the Familial Hypercholesterolemia Case Ascertainment Tool (FAMCAT): Protocol for a Mixed Methods Evaluation Study.
Ramli AS, Qureshi N, Abdul-Hamid H, Kamal A, Kanchau JD, Shahuri NS, Akyea RK, Silva L, Condon L, Abdul-Razak S, Al-Khateeb A, Chua YA, Mohamed-Yassin MS, Baharudin N, Badlishah-Sham SF, Abdul Aziz AF, Mohd Kasim NA, Sheikh Abdul Kadir SH, Kai J, Leonardi-Bee J, Nawawi H.
JMIR Res Protoc. 2023 Jun 2;12:e47911. doi: 10.2196/47911.
PMID:37137823
Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.
Tromp TR, Hartgers ML, Hovingh GK, Vallejo-Vaz AJ, Ray KK, Soran H, Freiberger T, Bertolini S, Harada-Shiba M, Blom DJ, Raal FJ, Cuchel M; Homozygous Familial Hypercholesterolaemia International Clinical Collaborators.
Lancet. 2022 Feb 19;399(10326):719-728. doi: 10.1016/S0140-6736(21)02001-8. Epub 2022 Jan 28.
PMID:35101175
© Copyright 2021 鸿泰茂源  版权所有All Rights Reserved京ICP备11040441号-3